Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 3,914 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Kidney, Polycystic
Interventions: Lisinopril, Telmisartan, Placebo, Standard Blood Pressure Control, Low Blood Pressure Control; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 15 Years to 64 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more

Conditions: Hypertension
Interventions: Pharmacy TEAM monitoring and counseling; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions: Levosimendan, Matching Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 16
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more

Conditions: Glaucoma
Interventions: TEMPO iMOvifa; Diagnostic Test
Lead sponsor: Cape Fear Eye Institute; Other
Eligibility: 40 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Hypertension, High Blood Pressure
Interventions: ROX Coupler, Sham procedure; Device · Other
Lead sponsor: ROX Medical, Inc.; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 13
States / cities: Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia + 9 more

Conditions: Ocular Hypertension
Interventions: Scleral Lens; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Blood Pressure, Hypertension
Interventions: Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Pulmonary Arterial Hypertension
Interventions: MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pulmonary Hypertension
Interventions: sitaxsentan sodium; Drug
Lead sponsor: Encysive Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Hypertension, Pulmonary Artery Pressure, Exercise Performance, Air Pollution
Interventions: sildenafil, placebo; Drug · Other
Lead sponsor: Marywood University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: Nanodropper, Regular dropper; Device
Lead sponsor: 59th Medical Wing; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lackland Air Force Base, Texas

Conditions: Hypercholesterolemia, Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glaucoma
Interventions: 0.005% Latanoprost dosed once.; Drug
Lead sponsor: Nanduri, Padma, M.D., FACS; Individual
Eligibility: 21 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Visalia, California

Conditions: Hypertension
Interventions: irbesartan, placebo, PS433540; Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 40
States / cities: Pell City, Alabama • Tempe, Arizona • Tucson, Arizona + 36 more

Conditions: Alzheimer Disease (AD), Cardio Vascular Disease, Mild Cognitive Impairment (MCI), Frailty Syndrome, Disability Physical, Hypertension, Metabolic Syndrome (MetS), Healthy Aging, Obesity &Amp; Overweight
Interventions: Not listed
Lead sponsor: Marymount University; Other
Eligibility: 50 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Arlington, Virginia

Conditions: Hypertension, Stress, Psychological, Blood Pressure
Interventions: Prazosin, Placebo; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Pre-Eclampsia, Obesity, Gestational Diabetes, Gestational Hypertension
Interventions: Women's Health Delaware Food Farmacy, Usual Standard of Care; Other
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Hypertension, Pulmonary
Interventions: Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator; Drug
Lead sponsor: Actelion; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Hypertension
Interventions: Nebivolol, Atenolol, Moxifloxacin; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypertension
Interventions: Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, Study# 2 chlorthalidone (CTD), fixed dose, Study# 2 spironolactone (SP), fixed dose, Study# 2 irbsesartan (IR), fixed dose; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Hypertension, Diastolic Dysfunction
Interventions: valsartan, amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: USA, New Jersey

Conditions: Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions: Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ocular Hypertension
Interventions: bimatoprost; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hypertensive Disease
Interventions: Potassium control diet, Potassium gluconate diet, Potato Diet, French Fries Diet; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: West Lafayette, Indiana

Search by objective public record fields.

HALT Progression of Polycystic Kidney Disease Study A

A Team Model of Hypertension Care in African Americans

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Glaucoma Screening

A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension

Intraocular Pressure in Ocular Hypertensives With Scleral Lens Wear

Reversing Glucose and Lipid-mediated Vascular Dysfunction

A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)

Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension

Does Sildenafil Increase Exercise Performance in Air Pollution?

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol

Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)

Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress

Evaluating the Effectiveness of a Food is Medicine Community Health Worker Program for Pregnant Women

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Retention of Potassium From Potatoes and Potassium Gluconate, and the Effect on Blood Pressure.